No products in the cart.
Initial effects of COVID-19 on patients with end-stage kidney disease
1. Patients with end-stage kidney disease were at increased risk of COVID-19-related mortality, particularly among non-Hispanic Black patients.
Evidence Rating Level: 3 (Average)
End-stage kidney disease (ESKD) has been a significant contributor to COVID-19 mortality, with global fatality estimates falling between 20 to 30% of COVID-19 patients with ESKD. This retrospective cohort study identified patients with ESKD from Centers for Medicare and Medicaid Services data during epidemiologic weeks 3 through 27 of 2017 through 2020, and corresponding weeks of 2017 through 2019. These patients were then stratified by kidney replacement therapy, with primary outcomes being COVID-19 hospitalization, all-cause death, and other hospitalizations. In week 3 of 2020, a total of 568,533 (40.0% aged 45 to 64 years, 31.9% non-Hispanic Black) patients were receiving dialysis and another 237,746 (48.4% aged 45 to 64 years, 20.2% non-Hispanic Black) had a functioning transplant. Patients undergoing dialysis demonstrated a peak COVID-19 hospitalization rate between March 22 and April 25, 2020. Non-Hispanic Black and Hispanic race were associated with higher rates of COVID-19 hospitalization, compared to other racial identities. Adjusted relative risks of death in 2020, compared to 2017-2019, were 1.17 (95% CI 1.16 to 1.19) for those undergoing dialysis and 1.30 (95% CI 1.24 to 1.36) for those with a functioning transplant. Excess mortality was also higher among non-Hispanic Black, Hispanic, and Asian patients during the study period. Overall, this study of patients with ESKD suggests an increased risk of negative outcomes both in terms of all-cause mortality as well as COVID-19 mortality. Further, racial differences were readily apparent – aligning with other COVID-19 studies – and clearly demonstrate disparities within this medical population.
Click to read the study in JASN
Image: PD
©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.
RelatedReports
![Macitentan better than placebo for preventing progression of pulmonary arterial hypertension [SERAPHIN Trial]](https://2minutemedicine-wpengine.netdna-ssl.com/wp-content/uploads/2013/08/ca68dc0329bef0b42ccae7b6656a0f_gallery-75x75.jpg)
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.